Journal Article Ppublish 33 citations
PubMed: 33690814 DOI: 10.1182/blood.2020008635
Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy.
Blood 137(21):2997-3001
Authors: Minke A E Rab, Jennifer Bos, Brigitte A van Oirschot, Stephanie van Straaten, Penelope A Kosinski, Victor Chubukov, Hyeryun Kim, Heidi Mangus, Roger E G Schutgens, Gerard Pasterkamp, Lenny Dang, Charles Kung, Eduard J van Beers, Richard van Wijk
Affiliations
- Central Diagnostic Laboratory-Research and.
- Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, The Netherlands; and.
- Agios Pharmaceuticals Inc, Cambridge, MA.
MeSH
Hematology, Anemia, Sickle Cell, Cells, Therapeutics, Pyruvate Kinase
Cited by
- Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. Blood Cells Mol Dis, 2022
- Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease. Eur J Pediatr, 2023
- Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med, 2021
- Use of the microfluidic impedance red cell assay in sickle cell disease. Blood Adv, 2025
- A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood, 2022
- Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease. Am J Hematol, 2025
- Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease. Blood, 2024
- One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. Blood Adv, 2023
- Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. Blood, 2022
- Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease. Hematology Am Soc Hematol Educ Program, 2023
- Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease. Blood Adv, 2024